NOVO NORDISK PHARMACEUTICALS A/S: Financial statements 2016
CVR: 24257924
Source: annual report 2016, Danish Business Authority
01/01/2016 – 31/12/2016
NOVO NORDISK PHARMACEUTICALS A/S (CVR 24257924) has filed annual accounts for 2016. In 2016, the company reported a net result of DKK 1,694,000 compared with DKK 1,879,000 the year before. Equity in the 2016 report amounted to DKK 16,116,000. The solvency ratio was 99.9%.
- Profit/Loss
- DKK 1,694,000
- Equity
- DKK 16,116,000
- Total Assets
- DKK 16,138,000
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2016 | - | - | 1.7M | 16.1M | - |
| 2015 | - | - | 1.9M | 14.4M | - |
| 2014 | - | - | 3.2M | 12.5M | - |
Official annual report
Find more companies like NOVO NORDISK PHARMACEUTICALS A/S
Build lead lists with filters on industry, geography, size and financials, and export straight to Excel.
Try the lead list generatorEvents in 2016
NOVO NORDISK PHARMACEUTICALS A/S has published its annual report for 2015. The net result was DKK 1,879,000.
About NOVO NORDISK PHARMACEUTICALS A/S
NOVO NORDISK PHARMACEUTICALS A/S is a Danish company of the type Aktieselskab based in Bagsværd, founded in 1974. The company is registered under the industry Anden finansiel formidling i.a.n.. The company was previously named NOVO FARMAKA A/S. The management consists of Anders Rytter Mikkelsen. The board consists of Naja Eilers Barrisøe (chair), Linette Tangsgaard Nielsen and Thomas Rask Nielsen. The company is owned by NOVO NORDISK A/S. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -53,000 and a net result of DKK 2,074,000 compared with DKK 6,918,000 the year before. Equity in the 2025 report amounted to DKK 12,325,000.
